Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 45.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 177,505 shares of the medical research company's stock after selling 148,442 shares during the quarter. Victory Capital Management Inc. owned 0.36% of Charles River Laboratories International worth $26,718,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in CRL. Signaturefd LLC increased its holdings in Charles River Laboratories International by 26.8% during the 1st quarter. Signaturefd LLC now owns 1,300 shares of the medical research company's stock worth $196,000 after purchasing an additional 275 shares during the period. New York State Common Retirement Fund boosted its position in shares of Charles River Laboratories International by 16.7% in the 1st quarter. New York State Common Retirement Fund now owns 131,820 shares of the medical research company's stock valued at $19,842,000 after purchasing an additional 18,894 shares during the period. Laurus Global Equity Management Inc. lifted its position in Charles River Laboratories International by 13.9% during the 1st quarter. Laurus Global Equity Management Inc. now owns 90,180 shares of the medical research company's stock worth $13,574,000 after acquiring an additional 11,030 shares during the period. MainStreet Investment Advisors LLC lifted its position in Charles River Laboratories International by 41.3% during the 1st quarter. MainStreet Investment Advisors LLC now owns 2,465 shares of the medical research company's stock worth $371,000 after acquiring an additional 720 shares during the period. Finally, Iridian Asset Management LLC CT lifted its position in Charles River Laboratories International by 18.5% during the 1st quarter. Iridian Asset Management LLC CT now owns 60,419 shares of the medical research company's stock worth $9,094,000 after acquiring an additional 9,454 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Down 3.1%

Shares of NYSE:CRL opened at $149.70 on Tuesday. The business has a 50-day moving average price of $147.42 and a 200 day moving average price of $150.35. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $7.35 billion, a price-to-earnings ratio of -230.31, a PEG ratio of 5.23 and a beta of 1.49. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the company posted $2.27 earnings per share. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

CRL has been the subject of several analyst reports. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research report on Wednesday, May 14th. Mizuho dropped their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. Evercore ISI increased their price target on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Finally, Barclays increased their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $174.54.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.